Sat, Dec 27, 2014, 2:14 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • bladerunner1717 bladerunner1717 May 17, 2013 5:38 AM Flag

    AZN offically announces taking Selumetinib into Phase III this year

    AstraZeneca Plc (AZN) will move three experimental cancer treatments into late-stage development as generic competition for its best-selling drugs intensifies.

    The U.K.’s second-biggest drugmaker is advancing development of moxetumomab pasudotox for hairy cell leukemia, olaparib for platinum-sensitive relapsed ovarian cancer and selumetinib for non-small cell lung cancer patients with the KRAS genetic mutation, the London-based company said today in a statement.
    Selumetinib, which the company licensed from Array Biopharma (ARRY), will begin testing in a late-stage trial in non-small cell lung cancer patients with a KRAS gene mutation during the second half of the year. AstraZeneca is also testing the treatment in melanoma patients with the same genetic mutation and for advanced pancreatic cancer


    Sentiment: Strong Buy

4.75+0.110(+2.37%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.